WO2022202403A1 - 口腔内ナイセリア・ムコサ増加剤 - Google Patents

口腔内ナイセリア・ムコサ増加剤 Download PDF

Info

Publication number
WO2022202403A1
WO2022202403A1 PCT/JP2022/010902 JP2022010902W WO2022202403A1 WO 2022202403 A1 WO2022202403 A1 WO 2022202403A1 JP 2022010902 W JP2022010902 W JP 2022010902W WO 2022202403 A1 WO2022202403 A1 WO 2022202403A1
Authority
WO
WIPO (PCT)
Prior art keywords
erythritol
xylitol
mannitol
nitrate
sugar alcohols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/010902
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
明彦 藤井
友基 赤津
早和子 河野
初美 惣野
慶彦 峯岸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to CN202280023964.0A priority Critical patent/CN117042781A/zh
Publication of WO2022202403A1 publication Critical patent/WO2022202403A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to an agent for increasing Neisseria mucosa in the oral cavity.
  • microorganisms build and live indigenous flora based on complex interactions.
  • the composition of the resident flora differs among individuals, and in recent years, the relationship between this individual difference and the health condition of the host has been pointed out and attracted attention.
  • the oral cavity like the intestine, is a microbial ecosystem in which a wide variety of bacteria coexist.
  • Several types of pathogenic bacteria have been identified for oral infections represented by dental caries and periodontal disease, and these bacteria also live symbiotically in the oral cavity as members of the normal ecosystem. Therefore, it is speculated that interactions with other indigenous bacteria in the environment play a major role in the onset of diseases.
  • the goal has been to eliminate pathogenic bacteria that directly cause disease. It is
  • Neisseria mucosa is a non-pathogenic indigenous bacteria in the oral cavity along with Neisseria spp. known to exist.
  • the present applicant has recently found that Neisseria mucosa cells or cultures thereof suppress the infection of periodontal pathogens to gingival cells and are useful for the prevention or treatment of periodontal disease (Patent document 1).
  • Neisseria bacteria possess nitrate reductase and nitrite reductase, and have the ability to reduce nitrate ions (NO 3 ⁇ ) to nitrite ions (NO 2 ⁇ ) and nitric oxide (NO). have been reported (Non-Patent Document 1).
  • Nitric oxide is an important compound that exerts effects such as intercellular communication, antibacterial action, biological defense against pathogens, vasodilatory action, muscle contractility, etc. in various parts of the body, especially antibacterial action against periodontal pathogens.
  • Non-Patent Documents 2-5 It is also expected to lower blood pressure based on the improvement of blood vessel function, and to improve or improve motor function based on the improvement or enhancement of muscle contractility (Non-Patent Documents 2-5). Therefore, it is useful to increase the intraoral content of Neisseria.
  • Non-Patent Document 6 potassium ions have the effect of reducing hypersensitivity of pulpal nerves, and potassium nitrate and the like are known to be effective for hypersensitivity.
  • many sugar alcohols have the effect of promoting saliva secretion and tooth remineralization, and erythritol, xylitol, and sorbitol are also reported to have a caries-preventing effect (Non-Patent Document 7).
  • Non-Patent Document 7 it has been reported that sugar alcohols such as erythritol have a biofilm formation inhibitory effect (Patent Document 2).
  • the effects of potassium nitrate and sugar alcohols on intraoral Neisseria spp. are not known at all.
  • Patent Document 1 Japanese Patent Application No. 2020-200517
  • Patent Document 2 JP-A-2005-29484
  • Non-Patent Document 1 Barth KR et al., Microbiology (2009), 155:4093-4103
  • Non-Patent Document 2 Carlstrom M et al., Acta Physiol (Oxf). (2016), 224: e13080
  • Non-Patent Document 3 Masaru Shibata, Agriculture and Science Apr. 2019, 1-8
  • Non-Patent Document 4 Omar SA et al., J Intern Med.
  • Non-Patent Document 5 CJ Backlund et al., J Dent Res 93(11):1089-1094, 2014
  • Non-Patent Document 6 Poulsen S et al., Cochrane Database Syst Rev.; (2006): CD001476
  • Non-Patent Document 7 Peter de Cock P et al., Int J Dent. (2016), 2016:9868421.
  • the present invention relates to the following 1) to 40).
  • An agent for increasing Neisseria mucosa in the oral cavity containing, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • An agent for increasing intraoral Neisseria bacteria comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • An oral flora-improving agent comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a periodontal pathogen infection inhibitor comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a prophylactic or ameliorating agent for periodontal disease comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a nitric oxide increasing agent comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a hypertensive preventive or ameliorating agent comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a motor function improving or improving agent containing, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • Non-therapeutic use of a combination of a nitrate-providing compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol to prevent or ameliorate hypertension.
  • a method for increasing intraoral Neisseria mucosa comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • a method for increasing intraoral Neisseria bacteria comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • a method for improving oral flora comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol to a subject in need thereof in effective amounts.
  • a method for inhibiting periodontal pathogen infection comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • a method for preventing or improving periodontal disease comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • a method for increasing nitric oxide comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • a method for preventing or improving hypertension comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • a method for improving or improving motor function comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • the present invention relates to providing a material useful for increasing the content of Neisseria mucosa in the oral cavity.
  • the present inventors have found that the content of Neisseria mucosa and the content of Neisseria bacteria in the oral cavity can be increased by combining a nitrate ion-providing compound with a specific sugar alcohol. It was found to be useful for the prevention or treatment of periodontal diseases.
  • the content of Neisseria mucosa and the content of Neisseria bacteria in the oral cavity can be increased, it is possible to prevent or treat periodontal disease.
  • the supply of nitric oxide it is possible to improve blood vessel function and skeletal muscle contractility, prevent or improve hypertension, and improve or improve motor function.
  • the nitrate ion-supplying compound includes compounds capable of producing nitrate ions when in contact with water, and nitrates are preferred.
  • Nitrates include, for example, alkali metal nitrates and alkaline earth metal nitrates. Specific examples include sodium nitrate, potassium nitrate, calcium nitrate, etc. Potassium nitrate is preferred.
  • Nitrates are preferably of synthetic origin, but may be of natural origin.
  • one or more selected from erythritol, xylitol and mannitol can be used as the sugar alcohol.
  • the sugar alcohol it is preferable to use at least erythritol from the viewpoint of increasing the content of Neisseria mucosa in the oral cavity.
  • Such a nitrate ion-providing compound and sugar alcohol are used in combination. It may also be a kit in which single formulations containing the amount of drug can be used simultaneously or separately at intervals. Preferably, it is in the form of a formulation.
  • the ratio of the combination of the nitrate ion-providing compound and the sugar alcohol can be appropriately selected. More preferably 5 parts by mass or more, more preferably 10 parts by mass or more, and preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less. Also, it is preferably 2.5 to 40 parts by mass, more preferably 5 to 20 parts by mass, and more preferably 10 to 20 parts by mass.
  • dental plaque suspensions containing dental plaque collected from healthy individuals are cultured in a medium containing potassium nitrate and various sugar alcohols (erythritol, xylitol, mannitol) alone or in combination to obtain dental plaque biomass.
  • potassium nitrate or various sugar alcohols alone, and when potassium nitrate and sorbitol or maltitol were used in combination, compared to the control group.
  • a combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol can be an oral Neisseria mucosa increasing agent, an oral Neisseria spp. increasing agent or an oral flora improving agent, It can be used for producing an oral Neisseria mucosa-enhancing agent, an oral Neisseria-spp.
  • a combination of a nitrate ion-providing compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol is used to increase oral Neisseria mucosa, increase oral Neisseria spp., or improve oral flora.
  • the use may be administration to a human or non-human animal, or use in a specimen derived therefrom, and may be therapeutic or non-therapeutic.
  • non-human animals include non-human mammals such as apes, other primates, mice, rats, horses, cows, pigs, sheep, dogs, cats, hamsters, and companion animals.
  • Neisseria mucosa is a Gram-negative coccus belonging to the genus Neisseria in the family Neisseria family, and is a non-pathogenic oral resident bacterium.
  • the Neisseria genus refers to non-pathogenic oral bacteria belonging to the Neisseria family Neisseria genus, and in addition to Neisseria mucosa, Neisseria sicca, Neisseria flava , Neisseria subflava, Neisseria flavescens, Neisseria elongata, and the like.
  • increase in oral Neisseria mucosa means that the content of Neisseria mucosa in the oral cavity is increased by activating the metabolism of at least Neisseria mucosa among oral Neisseria spp. means.
  • increase in intraoral Neisseria spp. means an increase in intraoral Neisseria spp.
  • oral flora improvement means that the content of oral Neisseria mucosa or oral Neisseria spp. increases, the physiological functions of Neisseria mucosa or oral Neisseria spp. It means that the bacterial flora changes in a direction that is good for the host.
  • the content of Neisseria mucosa can be determined, for example, by using the nitrate reductase gene (narG) of Neisseria mucosa as a target gene and measuring the copy number of the gene by real-time PCR, as shown in the examples described later. It can be calculated by determining the ratio to the copy number of the rRNA16S gene in all bacteria.
  • the content of Neisseria spp. is determined by measuring the copy number of the gene by real-time PCR using a probe that specifically detects the rRNA16S gene of all Neisseria spp. It can be calculated by finding the ratio of
  • Neisseria mucosa is useful for the prevention or treatment of periodontal disease because its bacterial cells or its culture suppresses the infection of periodontal pathogens to gingival cells and suppresses gingival inflammation ( Patent document 1).
  • Periodontal pathogens mean bacteria such as Porphyromonas gingivalis and Fusobacterium nucleatum that infect periodontal tissue and cause gingivitis and periodontal tissue destruction.
  • Neisseria bacteria have the ability to reduce nitrate ions (NO 3 - ) to nitrite ions (NO 2 - ) and nitric oxide (NO) (Non-Patent Document 1)
  • nitrate ion-supplying compounds is reduced to nitrite by Neisseria spp. and further converted to nitric oxide including nitric oxide.
  • Non-Patent Documents 2, 3, 4 Therefore, the oral Neisseria mucosa-enhancing agent, Neisseria-spp.
  • the preventive or ameliorating agent for periodontal disease exerts its effect by suppressing the infection of periodontal pathogens to gingival cells by Neisseria mucosa, so the amount of bactericide used can be suppressed, and it is safer. It can be an expensive formulation.
  • nitric oxide means increasing the innate nitric oxide concentration in the body.
  • Prevention or amelioration of decreased vascular function caused by nitric oxide deficiency e.g., vascular endothelial dysfunction, arteriosclerosis, etc.
  • associated pathologies hypertension, myocardial infarction, cerebral infarction, etc.
  • an increase in nitric oxide improves the contractility of skeletal muscles, making it possible to improve or improve motor function.
  • Periodontal disease means an inflammatory disease in which inflammation is induced in the gums by bacteria in dental plaque, and includes gingivitis and periodontitis.
  • prevention refers to preventing or delaying the onset of a disease or condition in an individual, or reducing an individual's risk of developing a disease or condition.
  • improvement means amelioration of a disease, symptom or condition, prevention or delay of worsening of a disease, symptom or condition, or reversal, prevention or delay of progression of a disease or symptom, and the concept of so-called “treatment” is included.
  • improvement means that the physical function, etc., from the present time goes in a better direction or in an excellent state.
  • the agent for increasing oral Neisseria mucosa the agent for increasing Neisseria spp., the agent for improving oral flora, the agent for preventing or improving periodontal disease, the agent for increasing nitric oxide, the agent for preventing or improving hypertension, and the agent for improving or improving motor function of the present invention.
  • the agent itself is for increasing oral Neisseria mucosa, for increasing oral Neisseria spp., for improving oral flora, for preventing or improving periodontal disease, and for increasing nitric oxide.
  • foods for the prevention or improvement of hypertension, or for the improvement or improvement of motor function, pharmaceuticals, quasi-drugs, foods, or oral compositions, and are incorporated in such pharmaceuticals, quasi-drugs, foods, or oral compositions It can be a material or formulation used as a
  • foods include: increase of oral Neisseria mucosa, increase of oral Neisseria spp., improvement of oral flora, suppression of periodontal pathogen infection, prevention or improvement of periodontal disease, increase of nitric oxide, prevention or improvement of hypertension , Foods with the concept of improving or enhancing motor function, etc., and labeled as necessary, foods with function claims, foods for specified health uses, foods for the sick, and supplements.
  • the form of oral administration is preferable, and the dosage form is, for example, a liquid agent; Various forms such as capsules containing solid agents, oral sprays, troches and the like are included.
  • the forms When used as a food, the forms include beverages such as fruit or vegetable juice drinks, carbonated drinks, tea drinks, milk drinks, fermented milk, fermented fruit juices, fermented vegetable juices, alcoholic beverages, soft drinks, jelly foods, and various other beverages.
  • beverages such as fruit or vegetable juice drinks, carbonated drinks, tea drinks, milk drinks, fermented milk, fermented fruit juices, fermented vegetable juices, alcoholic beverages, soft drinks, jelly foods, and various other beverages.
  • Various foods such as snacks, baked goods, cakes, chocolate, jam, bread, gum, candy, soups, pickles, and tsukudani, as well as forms similar to those for oral administration (tablets, capsules, syrups, etc.) supplements, etc.
  • oral composition examples include mouthwash, mouthwash, toothpaste, toothpaste, toothpaste, oral ointment, gel, tablet, granule, fine granule, gummy jelly, Examples include troches, tablets, capsules, candies, chewing gums, etc., preferably toothpaste, mouthwash, gummy jelly, and troches.
  • the pharmaceuticals, quasi-drugs, foods, and oral compositions contain nitrate ion-providing compounds and one or more sugar alcohols selected from erythritol, xylitol, and mannitol as other active ingredients, pharmaceuticals, foods, etc. It can be prepared according to a conventional method by appropriately combining with additives used, arbitrary food materials, and the like.
  • the contents of the nitrate ion-providing compound and sugar alcohol in the pharmaceuticals, quasi-drugs, foods, and oral compositions are not particularly limited, and may be appropriately adjusted according to the daily dosage.
  • the intake or dosage can be appropriately determined according to various conditions such as patient weight, age, sex, and symptoms. 60 mg or more, preferably 200 mg or more, more preferably 600 mg or more, and 6000 mg or less, preferably 2000 mg or less, more preferably 1000 mg or less of the nitrate ion supplying compound per day.
  • the sugar alcohol is 300 mg or more, preferably 1000 mg or more, more preferably 3000 mg or more, and 30000 mg or less, preferably 10000 mg or less, more preferably 5000 mg or less.
  • Oral Neisseria mucosa increasing agent of the present invention oral Neisseria spp. increasing agent, oral flora improving agent, periodontal pathogen infection inhibitor, periodontal disease preventing or improving agent, nitric oxide increasing agent, hypertension prevention or
  • the agent to improve or improve motor function is preferably applied to humans infected with periodontal pathogens, humans developing gingivitis such as gingivitis or periodontitis, and developing gingivitis. people who want to prevent hypertension, people who want to lower blood pressure, people who want to improve or improve motor function, and the like.
  • An agent for increasing intraoral Neisseria bacteria which comprises, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • An oral flora-improving agent comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a periodontal pathogen infection inhibitor comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a prophylactic or ameliorating agent for periodontal disease comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a nitric oxide increasing agent comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a hypertensive preventive or ameliorating agent comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a motor function-improving or improving agent containing, as active ingredients, a nitrate ion-providing compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a food for increasing intraoral Neisseria mucosa containing as active ingredients a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a food for increasing intraoral Neisseria bacteria containing as active ingredients a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a food product for improving oral flora comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a food for suppressing infection with periodontal pathogens containing as active ingredients a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a food for preventing or improving periodontal disease containing as active ingredients a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a nitric oxide-increasing food containing, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a food for preventing or improving hypertension comprising, as active ingredients, a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • a food for improving or improving motor function containing as active ingredients a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol.
  • ⁇ 17> Use of a combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for producing an oral Neisseria mucosa increasing agent or an oral Neisseria mucosa increasing food.
  • ⁇ 18> Use of a combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for producing an agent for increasing intraoral Neisseria spp. or a food for increasing intraoral Neisseria spp.
  • ⁇ 19> Use of a combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for producing an agent for improving oral flora or a food for improving oral flora.
  • ⁇ 20> Use of a combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for producing a periodontal pathogen infection inhibitor or food for periodontal pathogen infection inhibition.
  • ⁇ 23> Use of a combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for producing an agent for preventing or improving hypertension or a food for preventing or improving hypertension.
  • ⁇ 24> Use of a combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for producing an agent for improving or improving motor function or a food for improving or improving motor function.
  • ⁇ 25> A combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in increasing intraoral Neisseria mucosa.
  • ⁇ 26> A combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in increasing intraoral Neisseria bacteria.
  • ⁇ 27> A combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in improving oral flora.
  • ⁇ 28> A combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in suppressing periodontal pathogen infection.
  • ⁇ 29> A combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in preventing or improving periodontal disease.
  • ⁇ 30> A combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in increasing nitric oxide.
  • ⁇ 31> A combination of a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in preventing or improving hypertension.
  • ⁇ 32> A combination of a nitrate ion-providing compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol for use in improving or enhancing motor function.
  • ⁇ 41> A method for increasing intraoral Neisseria mucosa, comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • ⁇ 42> A method for increasing intraoral Neisseria bacteria, comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • ⁇ 43> A method for improving oral flora comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol to a subject in need thereof in effective amounts.
  • a method for suppressing periodontal pathogen infection comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol to a subject in need thereof in effective amounts.
  • ⁇ 45> A method for preventing or improving periodontal disease, comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol to a subject in need thereof in effective amounts.
  • ⁇ 46> A method for increasing nitric oxide, comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol to a subject in need thereof in effective amounts.
  • a method for preventing or improving hypertension comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol in effective amounts to a subject in need thereof.
  • a method for improving or improving motor function comprising administering or ingesting a nitrate ion supplying compound and one or more sugar alcohols selected from erythritol, xylitol and mannitol to a subject in need thereof in effective amounts.
  • the sugar alcohol is preferably erythritol, erythritol and xylitol, erythritol and mannitol, or erythritol, xylitol and mannitol.
  • the nitrate ion supplying compound is preferably a nitrate, more preferably sodium nitrate or potassium nitrate.
  • the ratio of the combination of the nitrate ion-providing compound and the sugar alcohol is preferably 2.5 parts by mass or more of the sugar alcohol per 1 part by mass of the nitrate ion-providing compound. It is preferably 5 parts by mass or more, more preferably 10 parts by mass or more, and preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less. Also, it is preferably 2.5 to 40 parts by mass, more preferably 5 to 20 parts by mass, and more preferably 10 to 20 parts by mass.
  • the intake or dosage of the nitrate ion-providing compound and the sugar alcohol is 60 mg or more, preferably 200 mg or more, more preferably 600 mg or more per adult per day as the nitrate ion-providing compound. is 6000 mg or less, preferably 2000 mg or less, more preferably 2000 mg or less, and the sugar alcohol is 300 mg or more, preferably 1000 mg or more, more preferably 3000 mg or more, and 30000 mg or less, preferably 10000 mg or less, more preferably 5000 mg or less. is.
  • the improvement of the oral flora is an increase in the content of intraoral Neisseria mucosa or intraoral Neisseria spp.
  • Plaque collection and pretreatment Plaque adhering to the tooth surface was collected from a healthy male in his twenties using a dental scaler. The cells were placed in a 1.5 mL tube and washed twice with PBS(-) by centrifugation at 7,000 g for 2 minutes at room temperature. The plaque-containing pellet was suspended in 300 ⁇ L of CELLBANKER 1Plus (Juji Field), and the prepared plaque suspension was stored at ⁇ 80° C. until use.
  • plaque biofilm model by plaque suspension culture Tests of potassium nitrate (Wako), erythritol (Wako), xylitol (Wako), mannitol (Wako), sorbitol (Wako), and maltitol (Wako)
  • the plaque suspension was diluted 1000-fold with a compound-dissolved Brain Heart Infusion (BHI) medium (Japan BD) to prepare a culture solution containing bacterial cells.
  • BHI Brain Heart Infusion
  • Neisseria mucosa and Neisseria bacteria were quantified by real-time PCR using Taqman probes.
  • Taqman probes and primers were prepared (Table 1).
  • Taqman probes and primers for specifically detecting the rRNA16S gene of all Neisseria species were also prepared (Table 1).
  • Taqman probes and primers for detecting the rRNA16S gene of all bacteria were prepared with sequences described in a previous report (Nadkarni, MA, et al. Microbiology (2002) 148, 257-266) (Table 1).
  • Table 2 shows the reaction solution composition and reaction conditions for real-time PCR.
  • a calibration curve is prepared using a PCR product with a known copy number as a standard, and the copy number of the Neisseria mucosa nitrate reductase gene (narG) and the rRNA16S gene of the Neisseria spp. and the rRNA16S gene of all bacteria are calculated, Neisseria mucosa content rate and Neisseria content rate were calculated by the following formula.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2022/010902 2021-03-23 2022-03-11 口腔内ナイセリア・ムコサ増加剤 Ceased WO2022202403A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280023964.0A CN117042781A (zh) 2021-03-23 2022-03-11 口腔内粘液奈瑟菌增加剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021-049259 2021-03-23
JP2021049259 2021-03-23
JP2021201868 2021-12-13
JP2021-201868 2021-12-13

Publications (1)

Publication Number Publication Date
WO2022202403A1 true WO2022202403A1 (ja) 2022-09-29

Family

ID=83397124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/010902 Ceased WO2022202403A1 (ja) 2021-03-23 2022-03-11 口腔内ナイセリア・ムコサ増加剤

Country Status (3)

Country Link
JP (2) JP7827494B2 (cg-RX-API-DMAC7.html)
TW (1) TW202304477A (cg-RX-API-DMAC7.html)
WO (1) WO2022202403A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025197224A1 (ja) * 2024-03-22 2025-09-25 花王株式会社 口腔用組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025146213A (ja) * 2024-03-22 2025-10-03 花王株式会社 口腔用組成物
JP2025146214A (ja) * 2024-03-22 2025-10-03 花王株式会社 口腔内菌叢改善剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004026816A (ja) * 2002-05-08 2004-01-29 Sunstar Inc 口腔用組成物
JP2011105690A (ja) * 2009-11-20 2011-06-02 Lion Corp 液体口腔用組成物
JP2012188377A (ja) * 2011-03-10 2012-10-04 Kao Corp 口腔用組成物
JP2015157768A (ja) * 2014-02-21 2015-09-03 学校法人大阪歯科大学 口腔用組成物、歯周病疾患リスク予測装置および動物の歯周病治療方法
US20160151428A1 (en) * 2013-05-04 2016-06-02 Board Of Regents, The University Of Texas System Compositions and methods for promoting nitric oxide production through an oral delivery system
WO2017002891A1 (ja) * 2015-06-30 2017-01-05 日油株式会社 矯味剤およびこれを含有する口腔用組成物
JP2018530517A (ja) * 2015-08-28 2018-10-18 ネイチャーズ サンシャイン プロダクツ、インク. 一酸化窒素レベルを急激に上昇させるための組成物および方法
JP2021020869A (ja) * 2019-07-26 2021-02-18 ライオン株式会社 口腔内常在菌の生育促進剤及び口腔用組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4865991B2 (ja) * 2004-02-18 2012-02-01 花王株式会社 共凝集抑制剤
JP7290906B2 (ja) * 2015-02-13 2023-06-14 ロート製薬株式会社 歯根膜再生剤及びその製造方法
WO2020115974A1 (ja) * 2018-12-04 2020-06-11 花王株式会社 口腔用組成物
KR102299387B1 (ko) * 2019-07-16 2021-09-07 (주)한일제약 향균성 치약 조성물

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004026816A (ja) * 2002-05-08 2004-01-29 Sunstar Inc 口腔用組成物
JP2011105690A (ja) * 2009-11-20 2011-06-02 Lion Corp 液体口腔用組成物
JP2012188377A (ja) * 2011-03-10 2012-10-04 Kao Corp 口腔用組成物
US20160151428A1 (en) * 2013-05-04 2016-06-02 Board Of Regents, The University Of Texas System Compositions and methods for promoting nitric oxide production through an oral delivery system
JP2015157768A (ja) * 2014-02-21 2015-09-03 学校法人大阪歯科大学 口腔用組成物、歯周病疾患リスク予測装置および動物の歯周病治療方法
WO2017002891A1 (ja) * 2015-06-30 2017-01-05 日油株式会社 矯味剤およびこれを含有する口腔用組成物
JP2018530517A (ja) * 2015-08-28 2018-10-18 ネイチャーズ サンシャイン プロダクツ、インク. 一酸化窒素レベルを急激に上昇させるための組成物および方法
JP2021020869A (ja) * 2019-07-26 2021-02-18 ライオン株式会社 口腔内常在菌の生育促進剤及び口腔用組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARTH KENNETH R., ISABELLA VINCENT M., CLARK VIRGINIA L.: "Biochemical and genomic analysis of the denitrification pathway within the genus Neisseria", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, vol. 155, no. 12, 1 December 2009 (2009-12-01), Reading , pages 4093 - 4103, XP055970803, ISSN: 1350-0872, DOI: 10.1099/mic.0.032961-0 *
EMBRIETTE R. HYDE, FERNANDO ANDRADE, ZALMAN VAKSMAN, KAVITHA PARTHASARATHY, HONG JIANG, DEEPA K. PARTHASARATHY, ASHLEY C. TORREGRO: "Metagenomic Analysis of Nitrate-Reducing Bacteria in the Oral Cavity: Implications for Nitric Oxide Homeostasis", PLOS ONE, vol. 9, no. 3, pages e88645, XP055289203, DOI: 10.1371/journal.pone.0088645 *
ONYANGO STANLEY O., DE CLERCQ NELE, BEERENS KOEN, VAN CAMP JOHN, DESMET TOM, VAN DE WIELE TOM: "Oral Microbiota Display Profound Differential Metabolic Kinetics and Community Shifts upon Incubation with Sucrose, Trehalose, Kojibiose, and Xylitol", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 86, no. 16, 3 August 2020 (2020-08-03), US , pages 1 - 14, XP055970801, ISSN: 0099-2240, DOI: 10.1128/AEM.01170-20 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025197224A1 (ja) * 2024-03-22 2025-09-25 花王株式会社 口腔用組成物

Also Published As

Publication number Publication date
TW202304477A (zh) 2023-02-01
JP2022151714A (ja) 2022-10-07
JP7827494B2 (ja) 2026-03-10
JP2026074308A (ja) 2026-05-01

Similar Documents

Publication Publication Date Title
JP5879349B2 (ja) 口腔衛生のためのプロバイオティック組成物
JP7698984B2 (ja) リステリア感染症の予防又は改善剤
CN104023732B (zh) 口腔疾患的预防或治疗剂
CN107075455B (zh) 具有抗炎症及代谢疾病改善功效的植物乳杆菌hac01菌株及其用途
JP7827494B2 (ja) 口腔内ナイセリア・ムコサ増加剤
KR102217525B1 (ko) 치주염 예방 또는 치료용 유산균 및 그의 용도
US8668906B2 (en) Lactobacillus plantarum strains as hypocholesterolemic agents
WO2003082027A1 (en) Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods
CN1860219A (zh) 乳酸杆菌在减少龋齿和细菌引发龋齿中的用途
JP2023132273A (ja) 口腔内アクチノマイセス属及びロシア属菌増加剤
JPWO2008105113A1 (ja) 口腔内用殺菌剤、及び該殺菌剤を含有する食品添加剤
JP2022185502A (ja) ピロリ菌感染症の予防又は改善剤
CN100586297C (zh) 抗牙周病菌组合物
KR102001074B1 (ko) 충치 억제 활성을 갖는 유산균 조성물
JP2013103880A (ja) 抗酸化機能賦活剤
JP5544234B2 (ja) 歯周病菌生育抑制用組成物
KR102217518B1 (ko) 치주염 예방 또는 치료용 유산균 및 그의 용도
WO2023002939A1 (ja) 炎症性腸疾患の予防又は改善のための組成物、及び腸内細菌叢調節のための組成物
JP2017109973A (ja) 機能性胃腸症改善剤
TWI705135B (zh) 抗齲齒劑及抗齲齒用組成物
JP2025134209A (ja) 口腔菌叢改善剤
CN117042781A (zh) 口腔内粘液奈瑟菌增加剂
JP2018150282A (ja) 口腔用組成物
JP7725198B2 (ja) 歯周病の予防又は改善剤
KR102329670B1 (ko) 열처리 가공염을 포함하는 구강내 균총 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22775195

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2301005976

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 202280023964.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22775195

Country of ref document: EP

Kind code of ref document: A1